Please provide your email address to receive an email when new articles are posted on . Minimally invasive surfactant therapy did not lower mortality among preterm infants with respiratory distress ...

Objective: The aim of the study was to measure pulmonary mechanics in infants with respiratory distress syndrome before extubation and to correlate pulmonary function values with successful extubation ...

The article as published, omitted the length of stay data and reported only the mortality data. It does have multiple regression analyses ‘correcting’ for possible differences in risk among patients ...

THE respiratory-distress syndrome, or hyalinemembrane disease, is the commonest cause of death among newborn, especially premature, infants, and yet its pathogenesis remains a mystery and its ...

The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant ...

The intubation-surfactant-extubation (INSURE) procedure is used worldwide to treat preterm newborn infants suffering from respiratory distress syndrome, which is caused by an insufficient amount of ...

HealthDay News — The FDA has approved Surfaxin (lucinactant) to prevent respiratory distress syndrome (RDS) in premature infants. Premature infants born before 37 weeks’ gestation often cannot produce ...

We performed complete SFTPC resequencing, including the promoter and intervening introns, for 269 infants (92 RDS, 177 CON). Interim analyses revealed overrepresentation in the cases of the minor ...

Holly Jordan's premature son survived — thanks to medical advances after Patrick Kennedy's death from Infant Respiratory Distress Syndrome decades earlier Holly Jordan, who works in business ...

Please provide your email address to receive an email when new articles are posted on . Researchers observed high lysolipid levels in those with acute respiratory distress syndrome (ARDS), which may ...